Product image of Mesi-2 (Metformin Hydrochloride, Sitagliptin) supplied by GNH India

Mesi-2

Active Ingredient:
Metformin Hydrochloride, Sitagliptin
Origin:
EU

Mesi-2 (Metformin Hydrochloride, Sitagliptin)

Metformin Hydrochloride / Sitagliptin, the active ingredient in Mesi-2, is a Biguanide / DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults, helping to improve glycaemic control when used with diet and exercise.

GNH India supplies Mesi-2 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Nassington Ltd

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mesi-2 is used in the treatment of type 2 diabetes mellitus, a chronic metabolic disorder affecting glucose regulation.

  • Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels.
  • Inadequate control on metformin alone: provides additional glucose reduction when added to existing therapy.
  • Combination therapy in adults: simplifies regimen and may improve medication adherence.

How It Works

  • Metformin Hydrochloride reduces hepatic gluconeogenesis and enhances peripheral insulin sensitivity, while Sitagliptin inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), leading to increased levels of endogenous incretins (GLP‑1 and GIP). The elevated incretins promote glucose‑dependent insulin secretion and suppress glucagon release, together producing improved glycaemic control.

Side Effects

Mesi-2 may cause a range of adverse reactions, from mild to serious.

Common Side Effects

  • Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea.
  • Headache: mild to moderate intensity.
  • Mild hypoglycaemia: especially when combined with insulin or sulfonylureas.
  • Metallic taste: transient alteration in taste perception.
  • Upper respiratory tract symptoms: nasopharyngitis or cough.

Serious or Rare Side Effects

  • Lactic acidosis: a rare but life‑threatening metabolic complication.
  • Severe hypoglycaemia: can occur with concomitant insulin or sulfonylureas.
  • Pancreatitis: acute inflammation of the pancreas.
  • Allergic reactions: rash, pruritus, or angio‑edema.
  • Hepatic dysfunction: elevated liver enzymes or hepatitis.
  • Renal impairment: worsening kidney function, particularly with metformin accumulation.

Precautions & Warnings

Before prescribing Mesi-2, clinicians should evaluate patient‑specific risk factors and monitor for potential complications.

  • Renal function: assess baseline creatinine clearance and monitor periodically.
  • Lactic acidosis risk: avoid in patients with severe renal or hepatic impairment.
  • Hypoglycaemia monitoring: especially when used with insulin or sulfonylureas.
  • Pregnancy and lactation: consider only if benefits outweigh potential risks.
  • Vitamin B12 levels: monitor during long‑term metformin therapy.
  • Store at ambient temperature: keep in the original container, protect from moisture.

Avoid Interactions

Mesi-2 can interact with several medicines, requiring careful management.

Major Interactions (Avoid)

  • Concomitant insulin or sulfonylureas: increased risk of severe hypoglycaemia.
  • Iodinated contrast agents in patients with renal impairment: may precipitate metformin‑associated lactic acidosis.
  • Other DPP‑4 inhibitors: additive pharmacologic effect, not recommended.

Moderate Interactions (Monitor Closely)

  • Cimetidine or other renal tubular secretion inhibitors: may raise metformin plasma concentrations.
  • Diuretics: can affect glucose control and electrolyte balance.
  • ACE inhibitors or ARBs: may increase risk of renal dysfunction when combined with metformin.

Frequently Asked Questions

Mesi-2 is a prescription oral medication indicated for the treatment of type 2 diabetes mellitus in adults. It combines metformin and sitagliptin to improve blood glucose control when diet, exercise, and lifestyle measures alone are insufficient.

Metformin lowers hepatic glucose production and increases insulin sensitivity in peripheral tissues. Sitagliptin blocks the DPP‑4 enzyme, raising levels of incretin hormones (GLP‑1 and GIP) that stimulate insulin release and reduce glucagon secretion, together enhancing glycaemic control.

The specific dose of Mesi-2 is determined by the prescribing healthcare professional based on individual patient factors such as renal function, current glycaemic control, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of Mesi-2 in pregnancy and lactation has not been definitively established. It should only be used if the potential benefits justify the potential risks to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To order Mesi-2, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Mesi-2 combines two mechanisms—biguanide action of metformin and DPP‑4 inhibition of sitagliptin—offering complementary glucose‑lowering effects. Compared with monotherapy agents, the combination can provide greater HbA1c reduction and simplify dosing, though individual patient response and tolerance must be considered.

Mesi-2 should be stored at ambient temperature, below 25 °C, in its original blister pack or container. Protect the tablets from moisture and direct sunlight to maintain stability throughout the product’s shelf life.

Mesi-2 is taken orally, usually once daily with or without food, as directed by the prescriber. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically advised.

The most serious risks include lactic acidosis from metformin, especially in patients with renal or hepatic impairment, and severe hypoglycaemia when used with insulin or sulfonylureas. Pancreatitis and allergic reactions are also rare but potentially serious adverse events.

Mesi-2 is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin or sitagliptin, and those with a history of lactic acidosis. Caution is also advised for individuals with significant hepatic disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT